Form 4 for STLN Starling Oncology, Inc.
Accepted 2022-10-25 00:00:00 ET · period of report 2022-10-24 · accession 0001628280-22-027011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-10-25 | 2022-10-24 | STLN | Kaushal Mohit | Dir | S - Sale | $4.96 | -4,798 | 41.5K | -10% | -$23.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2022-10-24 | S | D | 4,798 | $4.96 | 41,528 | D | — | — | (F2) Price is the volume weighted average selling price of all sales by the Reporting Person on October 24, 2022 within a one-dollar range. Actual prices ranged from $4.62 to $5.18. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. |